Where do we stand in enzyme replacement therapy in Pompe's disease?

Neuromuscular Disorders

Volumn 20, Issue 12, 2010, Pages 773-774

  van der Ploeg, A T ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE;

ASSISTED VENTILATION; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; EARLY INTERVENTION; EDITORIAL; ENZYME REPLACEMENT; FORCED VITAL CAPACITY; GENE MUTATION; GENOTYPE; GLYCOGEN STORAGE DISEASE TYPE 2; HEART HYPERTROPHY; HUMAN; MOTOR PERFORMANCE; MUSCLE WEAKNESS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURVIVAL TIME;

ENZYME REPLACEMENT THERAPY; GLUCAN 1,4-ALPHA-GLUCOSIDASE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS;

EID: 78649360686     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2010.09.011     Document Type: Editorial

References (10)

1. Van den Hout H., Reuser A.J., Vulto A.G., Loonen M.C., Cromme-Dijkhuis A., Van der Ploeg A.T. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 2000, 356:397-398.
2. Van Capelle C.I., Van der Beek N.A.M.E., Hagemans M.L.C., et al. Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open label study. Neuromuscul Disord 2010, 20:775-782.
3. Van der Ploeg A.T., Clemens P.R., Corzo D., et al. A randomized study of alglucosidase Alfa in late onset Pompe's disease. N Engl J Med 2010, 362:1396-1406.
4. Kishnani P.S., Corzo D., Nicolino M., et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007, 68:99-109.
5. Kishnani P.S., Corzo D., Leslie N.D., et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res 2009 Sep, 66(3):329-335.
6. Hagemans M.L., Hop W.J., Van Doorn P.A., Reuser A.J., Van der Ploeg A.T. Course of disability and respiratory function in untreated late-onset Pompe disease. Neurology 2006, 66:581-583.
7. Wokke J.H., Escolar D.M., Pestronk A., et al. Clinical features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve 2009, 38:1236-1245.
8. Van der Beek N.A., Hagemans M.L., Reuser A.J., et al. Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscul Disord 2009, 19:113-117.
9. Van Capelle C.I., Winkel L.P., Hagemans M.L., et al. Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease. Neuromuscul Disord 2008, 18:447-45222.
10. Strothotte S., Strigl-Pill N., Grunert B., et al. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 2009, 257:91-97.